Loading
companiesCompany
Iambic Therapeutics
AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2/4 inhibitor.
Overview
Iambic Therapeutics, based in San Diego, has AI-discovered oncology molecules in the clinic, including a HER2 inhibitor and a CDK2 and CDK4 inhibitor. IAM1363, a brain-penetrant HER2 inhibitor, and IAM-H1 entered phase 1 between 2024 and 2025, and its NeuralPLexer models predict structure and binding. OnCo links it to HER2 as a target and to AI-driven drug and target discovery. Whether a brain-penetrant HER2 inhibitor can treat brain metastases better than existing HER2 drugs is the clinical question that matters most. The HER2 target page carries the competitive field.
Similar pages
- CompanyGenesis Molecular AI (formerly Genesis Therapeutics)
Shares AI-driven drug & target discovery and the tag ai.
- CompanyLila Sciences
Shares AI-driven drug & target discovery and the tag ai.
- CompanyCradle
Shares AI-driven drug & target discovery and the tag ai.
- CompanyLatent Labs
Shares AI-driven drug & target discovery and the tag ai.
- CompanyProfluent
Shares AI-driven drug & target discovery and the tag ai.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares AI-driven drug & target discovery and the tag ai.
- PersonRegina Barzilay
Shares AI-driven drug & target discovery and the tag ai.